公开(公告)号：EP3087065B1

公开(公告)日：2020-01-22

申请号：EP14828105.8

申请日：2014-12-22

申请人： Amazentis SA

发明人： RINSCH, Christopher, L. ,  MÜLLER, Roland ,  SKRANC, Wolfgang

IPC分类号： C07D311/80

公开(公告)号：EP2866804A2

公开(公告)日：2015-05-06

申请号：EP13735543.4

申请日：2013-06-27

申请人： Amazentis SA

发明人： RINSCH, Christopher, L. ,  BLANCO-BOSE, William ,  SCHNEIDER, Bernard ,  MOUCHIROUD, Laurent ,  RYU, Dongryeol ,  ANDREUX, Penelope ,  AUWERX, Johan

IPC分类号： A61K31/366 ,  A61K45/06 ,  A61K31/00 ,  C07D493/00 ,  C07D493/06 ,  A61P9/00 ,  A61P29/00 ,  A61P25/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P35/00 ,  A61P43/00

CPC分类号： A61K31/37 ,  A61K31/00 ,  A61K31/366 ,  A61K31/7048 ,  A61K45/06 ,  C07D311/80 ,  A61K2300/00

摘要： Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

公开(公告)号：EP4395771A1

公开(公告)日：2024-07-10

申请号：EP22823616.2

申请日：2022-08-30

申请人： Amazentis SA

发明人： RINSCH, Christopher, L. ,  SINGH, Anurag ,  D'AMICO, Davide

IPC分类号： A61K31/37 ,  A61P31/14 ,  A61P31/12 ,  A61P31/22 ,  A61P21/00 ,  A61K31/122 ,  A61K31/375 ,  A61K31/7084 ,  A61K31/706 ,  A61K33/30

CPC分类号： A61K31/37 ,  A61P31/14 ,  A61P31/12 ,  A61P31/22 ,  A61P21/00 ,  A61K31/375 ,  A61K31/122 ,  A61K31/7084 ,  A61K31/706 ,  A61K33/30

公开(公告)号：EP2654461B1

公开(公告)日：2018-04-11

申请号：EP11808119.9

申请日：2011-12-23

申请人： Amazentis SA

发明人： ANDREUX, Penelope ,  SCHNEIDER, Bernard ,  RINSCH, Christopher, L. ,  SANDI, Carmen ,  AUWERX, Johan ,  PIRINEN, Eija ,  THOMAS, Charles ,  HOUTKOOPER, Richardus ,  BLANCO-BOSE, William ,  MOUCHIROUD, Laurent ,  GENOUX, David

IPC分类号： A23L33/105

CPC分类号： A61K31/366 ,  A23L33/105 ,  A23V2002/00 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0056 ,  A61K31/352 ,  A61K31/7048 ,  A61K36/185 ,  Y02A50/401

摘要： Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

公开(公告)号：EP3087065A2

公开(公告)日：2016-11-02

申请号：EP14828105.8

申请日：2014-12-22

申请人： Amazentis SA

发明人： RINSCH, Christopher, L. ,  MÜLLER, Roland ,  SKRANC, Wolfgang

IPC分类号： C07D311/80

CPC分类号： C07D311/80 ,  A61K31/366 ,  A61K33/34

摘要： Disclosed is a method of preparing a urolithin, or an intermediate or analog thereof, having a dibenzo[b,d]pyran-6-one core. The method is especially advantageous for the large-scale preparation of urolithins or intermediates or analogs thereof. The method may optionally include the preparation of a urolithin, or an intermediate or analog thereof, as a pharmaceutically acceptable salt.

摘要翻译： 公开了制备具有二苯并[b，d]吡喃-6-酮核心的尿石素或其中间体或类似物的方法。 该方法对于大规模制备尿石素或其中间体或类似物是特别有利的。 该方法可以任选地包括制备尿石素或其中间体或类似物作为药学上可接受的盐。

公开(公告)号：EP2654461A2

公开(公告)日：2013-10-30

申请号：EP11808119.9

申请日：2011-12-23

申请人： Amazentis SA

发明人： ANDREUX, Penelope ,  SCHNEIDER, Bernard ,  RINSCH, Christopher, L. ,  SANDI, Carmen ,  AUWERX, Johan ,  PIRINEN, Eija ,  THOMAS, Charles ,  HOUTKOOPER, Richardus ,  BLANCO-BOSE, William ,  MOUCHIROUD, Laurent ,  GENOUX, David

IPC分类号： A23L1/30 ,  A61K31/352 ,  A61K36/00 ,  A61K36/185

CPC分类号： A61K31/366 ,  A23L33/105 ,  A23V2002/00 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0056 ,  A61K31/352 ,  A61K31/7048 ,  A61K36/185 ,  Y02A50/401

摘要： Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

摘要翻译： 提供了组合物，其包括化合物或前体可用于为一个化合物。 各种治疗应用，包括，例如，治疗和/或预防与减少的或不充分的线粒体活性，包括老化或应激，糖尿病，肥胖，和神经变性疾病的疾病或病症。 化合物涉及基因集会urolithins和其前体，包括但不限于组合物被用于或用作食品或营养补充品呈现鞣花单宁和uroiithin A.某一实施方案。 这些相同的化合物和组合物，因此可以在基因集会健康净值的个人方便地用于增加或维持代谢率，减少身体脂肪百分比，增加或维持肌肉质量，管理体重，改善或保持心理的表现（包括内存），改善或维持肌肉 性能，改善或维持情绪，缓解压力。